My current research concentrates on the study of signal transduction pathways involved in prostate cancer development and progression. This includes studies on the EGFR family of receptor tyrosine kinases, leading to the PI3K/Akt pathway and finally to the mTOR signaling pathway. In particular, I investigate the interaction of these pathways with the androgen receptor. My research involves identification of significant therapeutic targets, as well as studying the effects of inhibitors of those targets both in vitro as well as in animal models. I am currently funded to study drug combinations that target parallel signaling pathways and in combination, appear to be highly effective in inhibiting the progression of prostate cancer.

Title:

Associate Professor

Specialty:

Cancer, Urologic Oncology, Urology

Center/Program Affiliation:

UC Davis Comprehensive Cancer Center

Other Languages:

Bengali

Education:

Rensselaer Polytechnic Institute
Troy, New York
Ph.D. 1994

Jadavpur University
Calcutta,
M.Sc. 1989

Jadavpur University
Calcutta,
B.Sc. 1987

Fellowships:

University of Texas Health Science Center
San Antonio, Texas
1994-2000
Pathology

Professional Memberships:

American Association for Cancer Research
American Association for the Advancement of Science
American Urological Association
The Society for Basic Urologic Research

Select Recent Publications:

Ghosh PM. What controls PTEN and what it controls (in prostate cancer). Asian J Androl. 2012 Jan;14(1):130-1. doi: 10.1038/aja.2011.122. Epub 2011 Sep 26.

Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem. 2011 Jun;11(2):131-149.

Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW. Dual blockade of PKA and NF-?B inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011 Aug;2(4):224-38.

Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res. 2011;1(4):542-61. Epub 2011 Mar 28.

Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 2011 Oct 1;17(19):6218-28. Epub 2011 Aug 15.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res. 2010 Jul 15;70(14):5994-6003. Epub 2010 Jun 29.

Chen H, Libertini SJ, George M, Dandekar S, Tepper CG, Al-Bataina B, Kung HJ, Ghosh PM, Mudryj M. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer. 2010 Oct 5;17(4):857-73. Print 2010 Dec.

Mooso B, Madhav A, Johnson S, Roy M, Moore ME, Moy C, Loredo GA, Mehta RG, Vaughan AT, Ghosh PM. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1a-Hydroxyvitamin D5 - a calcitriol analog. Genes Cancer. 2010 Nov 16;1(9):927-940.

Khan, IH, Ghosh, PM, Zhao, J, Ziman, M, Sweeney, C, Kung, HJ and Luciw, PA. Activation and Dimerization of Receptor Tyrosine Kinases (ErbB Family) in Breast Cancer Cells Analyzed by Multiplex Microbead Suspension Array. ASSAY and Drug Development Technologies, 8(1): 27-36. 2010

Chen, H., Libertini, S.J., Wang, Y., Kung, H.J., Ghosh, P.M., Mudryj, M. ERK regulates calpain 2 induced AR cleavage to LMW form in CWR22 relapsed prostate tumor cell lines. J. Biol. Chem., 285(4): 2368-74. 2010